Zheng Quan Zhi Xing·2025-07-27 16:14Group 1 - The core viewpoint of the article is that Citic Securities has conducted a review of Shanghai Kaisa Biotechnology Co., Ltd.'s differentiated dividend distribution plan for 2024, confirming its compliance with relevant laws and regulations [1][5] - The reason for the differentiated dividend distribution is the company's decision to repurchase shares using its own or raised funds, with a total repurchase amount between RMB 10 million and RMB 20 million [1][2] - As of the date of the review, the company has repurchased 2,341,165 shares, accounting for 0.32% of the total share capital of 721,289,794 shares [2][3] Group 2 - The differentiated dividend plan involves distributing a cash dividend of RMB 4 per 10 shares (including tax) to all shareholders, excluding the repurchased shares [2][3] - The total cash dividend to be distributed is approximately RMB 287.58 million (including tax), based on the adjusted total share capital after excluding repurchased shares [3] - The ex-dividend reference price is calculated to be approximately RMB 46.38 per share, with a minimal impact on the stock price due to the dividend distribution [4][5] Group 3 - The review by Citic Securities concludes that the differentiated dividend distribution plan aligns with the Company Law, Securities Law, and relevant self-regulatory guidelines, ensuring no harm to the interests of the company and its shareholders [5]